ESMO China’s Voice丨Dr. Jian Li’s Team Reports on Long-Term Follow-Up of the INTRIGUE China Bridging Study

ESMO China’s Voice丨Dr. Jian Li’s Team Reports on Long-Term Follow-Up of the INTRIGUE China Bridging Study

2024.09.22
Gastrointestinal stromal tumors (GIST) are mesenchymal tumors driven by mutations in oncogenes. In recent years, various types of small-molecule tyrosine kinase inhibitors (TKIs) have provided new treatment options for patients with advanced GIST, but there remains a significant unmet need in clinical care. During the 2024 ESMO Annual Meeting, Dr. Jian Li's team from Peking University Cancer Hospital presented updated data from the follow-up treatment analysis of the INTRIGUE China bridging study on ripretinib, offering further insights into the clinical application of such novel drugs.
ESMO 2024丨Subgroup Analysis from the ADRIATIC Study Further Supports Durvalumab Consolidation Therapy as a New Standard of Care for Limited-Stage Smal

ESMO 2024丨Subgroup Analysis from the ADRIATIC Study Further Supports Durvalumab Consolidation Therapy as a New Standard of Care for Limited-Stage Smal

2024.09.20
From September 13 to 17, the 2024 ESMO Annual Meeting is in full swing in Barcelona, Spain. Oncology Frontier is attending the event and bringing you first-hand insights from the conference. During the non-metastatic non-small cell lung cancer (NSCLC) paper session held on September 13, Dr. Suresh Senan from Amsterdam, Netherlands, presented the latest results from the ADRIATIC study, where subgroup analysis further supports previous practice-changing findings.
Isavuconazole for the Treatment of Cerebral Aspergillosis: A Retrospective European EFISG Study

Isavuconazole for the Treatment of Cerebral Aspergillosis: A Retrospective European EFISG Study

2024.09.17
Cerebral aspergillosis (CA) is a lethal invasive fungal infection, with current national and international guidelines recommending voriconazole as the first-line antifungal treatment. While newer triazoles, such as isavuconazole, demonstrate good blood-brain barrier penetration, there is still limited clinical evidence to confirm their efficacy and safety for treating CA. Recently, Clinical Infectious Diseases published a retrospective study led by the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The study highlights that isavuconazole is well-tolerated in the treatment of CA, with mortality rates comparable to those of voriconazole.
Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China

Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China

2024.09.17
In early September 2024, the 5th Tianjin International Lymphoma Conference was held from September 6 to 8, amid the golden season of autumn. This conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, creating a high-end academic platform for international exchange and collaboration. During the event, Hematology Frontier invited Dr. Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College to provide an in-depth analysis of the current state and future trends of CAR-T cell therapy in China from his academic perspective.
Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again

Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again

2024.09.17
The European Society for Medical Oncology Congress 2024(ESMO 2024) opened on September 13, in Barcelona,Spain. Lung cancer remains one of the key areas of focus,with several groundbreaking studies presented at the conference. Oncology Frontier invited Dr.Yuankai Shi, principal investigator of the INSPIRE study from the Cancer Hospital Chinese Academy of Medical Sciences,to share the latest data from this year's ESMO conference and discuss the clinical value of the study in treating anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer(NSCLC).
Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer

Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer

2024.09.15
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by high mortality rates and limited treatment options. Immunotherapy, particularly immune checkpoint blockade (ICB), has shown remarkable efficacy in treating cancers like melanoma and non-small cell lung cancer. However, many PDAC patients exhibit poor responses to ICB, mainly due to the tumor’s low immunogenicity and its immunosuppressive tumor microenvironment (TME). Inhibiting epigenetic regulators, such as SETDB1, KDM5B, and PHF8, has been shown to induce retrotransposon-mediated immune responses, thereby enhancing sensitivity to immunotherapy. While this approach shows promise in cancer treatment, its role in PDAC remains unclear. A recent study published in Gut identifies the key role of MED12 in modulating TME through the epigenetic silencing of retrotransposons, thus reshaping the immune TME in PDAC.
SOHO 2024丨Dr. Peihua Lu: CD7 CAR-T Cell Therapy Opens New Pathways to Cure, Reshaping the Future of T-Cell Malignancy Treatment

SOHO 2024丨Dr. Peihua Lu: CD7 CAR-T Cell Therapy Opens New Pathways to Cure, Reshaping the Future of T-Cell Malignancy Treatment

2024.09.15
The 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024. It brought together leading experts in hematologic oncology from around the world to discuss the latest research findings and explore new treatment strategies. Among the numerous topics discussed, the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) was a focal point due to the high relapse rate and treatment complexity associated with these diseases. Traditional treatments often fail to provide long-term remission, and CAR-T cell therapy faces the challenge of inadvertently targeting healthy T-cells, further complicating treatment.